drugset / Trial / NCT01647620
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
Phase 1
Terminated
30 enrolled
Diakron Pharmaceuticals
Kinesis Pharma B.V. · collabUniversity Ghent · collab
RandomizedQuadruple-blindTreatment
Summary
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-09
- Completion
- 2012-09
Outcome
Outcome not reported
Stopped (Business): “Diakron Pharmaceuticals couldn't fulfill the financial responsibility of the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DPOC-4088 | Small molecule | 100 mg | Oral |